Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 9, 2011 (rev. 1)

Premium

Steven Smith has been selected to serve as the executive vice president of bioinformatics at Orion Genomics.

Smith will lead Orion's efforts to develop bioinformatics tools that support its diagnostics and genomics services business units. Furthermore, he will direct the development of bioinformatics infrastructure to support new programs that use next-generation sequencing for high-resolution mapping of DNA methylation.

Prior to joining Orion, Smith was vice president of bioinformatics at NimbleGen (now part of Roche), where he led the development of bioinformatics tools for making custom arrays. He also worked at Millipore, Genetics Computer Group, and owned Genesmith Informatics, a consulting firm that specialized in bioinformatics support, software development, and genome analysis.

Smith served as the director of computation at the Harvard Genome Laboratory where he led the assembly and analysis of the Mycoplasma capricolum genome. He holds a BS in computer science engineering from the University of Illinois at Urbana-Champaign's school of engineering.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.